Pharmacy Phriday #9: Xofluza (Baloxavir marboxil) for Influenza

Pharmacy Phriday #9: Xofluza (Baloxavir marboxil) for Influenza

Contributor: Rachael Duncan, PharmD BCPS

Educational Pearls:

  • According to the Department of Public Health and Environment who puts out a weekly report on the influenza virus in Colorado, there appears to be less influenza in Colorado than previous years
  • A milder influenza outbreak is likely due to mask wearing and social distancing practices
  • There have only been 22 hospitalizations for influenza in Colorado since the start of the flu season back in September and 0 outbreaks in long-term care facilities
  • Xofluza (baloxavir marboxil) is an antiviral PA endonuclease inhibitor and was approved by the FDA in 2018 for uncomplicated influenza in patients 12 years and older that have been symptomatic for less than 48 hours
  • Patient's getting Xofluza must be otherwise healthy or at risk of developing influenza-related complications
  • Due to limited data, Xofluza would not be a good option for those that are inpatient or critically ill and is best utilized for patients who are being seen in the emergency department and will be sent home
  • Currently Xofluza is not approved for complicated patients, pregnant patients or those that are breast-feeding which limits its use
  • When compared with Tamiflu in phase 3 studies, Xofluza was superior to placebo and similar to Tamiflu in shortening the duration of illness
  • Xofluza is a single dose that is weight based and appears to be very well tolerated with some adverse effects including headache, nausea and diarrhea
  • Xofluza showed a quicker recovery compared to Tamiflu by 8 hours which could be related to its one-time dosing
  • Cost is a limiting factor for the use of Xofluza. Tamiflu costs around $25 where as Xofluza (only available as brand name currently) is $156 at the cheapest
  • Pharmacists are still encouraging everyone to get their influenza vaccines despite less influenza cases this year

References:

Cdphe.colorado.gov. 2021. Influenza (flu) | Department of Public Health & Environment. [online] Available at:

Ison, M., Portsmouth, S., Yoshida, Y., Shishido, T., Mitchener, M., Tsuchiya, K., Uehara, T. and Hayden, F., 2020. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 20(10), pp.1204-1214.

Hayden, F., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M., Hurt, A., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., Kawaguchi, K., Shishido, T., Arai, M., Tsuchiya, K., Uehara, T. and Watanabe, A., 2018. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), pp.913-923.

Summarized by Emily Mack OMSIII

The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at www.emergencymedicalminute.com/cme-courses/ and create an account.

Avsnitt(1146)

Podcast # 501: Take Down Potions

Podcast # 501: Take Down Potions

Author: Jared Scott, MD Educational Pearls: Study from Hennepin County EM studied the efficacy of different drugs for agitation, which included 737 patients Most patients in this study were male and ...

16 Sep 20193min

Colorado MAT Part 4: Buprenorphine in the Emergency Department

Colorado MAT Part 4: Buprenorphine in the Emergency Department

Treatment with buprenorphine is easier, less time consuming and far more effective for management of opioid withdrawal and OUD than standard care with clonidine, IVF, haldol and other symptomatic ther...

26 Aug 20191h 5min

Colorado MAT Part 3: Medications for MAT in the ED

Colorado MAT Part 3: Medications for MAT in the ED

There are three MAT drugs available to treat addiction: naltrexone (brand name Vivitrol), methadone (brand names Dolophine or Methadose) & buprenorphine (brand name Suboxone, Subutex, and Sublicade). ...

26 Aug 201927min

Colorado MAT Part 2: Medication Assisted Treatment

Colorado MAT Part 2: Medication Assisted Treatment

Medication Assisted Treatment or (Medication for Addiction Treatment) is an important frontier in ED care of patients with Opioid Use Disorder. Naltrexone, methadone and buprenorphine are the medicati...

26 Aug 201928min

Colorado MAT Part 1: Understanding Addiction & Opioid Use Disorder

Colorado MAT Part 1: Understanding Addiction & Opioid Use Disorder

Addiction is widely misunderstood by the public and by many healthcare providers. It is not taught in most medical schools. Combating the opioid epidemic will require providers to understand Opioid U...

26 Aug 201939min

Podcast #500: 2018-19 Rapid Fire EM Literature Review

Podcast #500: 2018-19 Rapid Fire EM Literature Review

Author: Dave Saintsing Educational Pearls: Poor sleep is an independent risk factor for development of health problems such as type 2 diabetes. A 2019 study, randomized participants to 3 groups: 9 h...

24 Aug 201914min

Podcast #499: Posterior Circulation Ischemia

Podcast #499: Posterior Circulation Ischemia

Podcast # 499: Posterior Circulation Strokes Contributor: Neal O'Connor, MD Educational Pearls: Dizziness is a very common complaint in the emergency department, but how can we find patients with a d...

22 Aug 201912min

Podcast # 498: Ortho Tips

Podcast # 498: Ortho Tips

Author: Susan Ryan, DO Educational Pearls: General orthopedic principles: Examine above and below the injury Document neurovascular status X-ray imaging typically requires three different views F...

19 Aug 201912min

Populärt inom Vetenskap

p3-dystopia
dumma-manniskor
svd-nyhetsartiklar
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
det-morka-psyket
rss-ufo-bortom-rimligt-tvivel
sexet
rss-vetenskapsradion
pojkmottagningen
rss-vetenskapsradion-2
dumforklarat
rss-broccolipodden-en-podcast-som-inte-handlar-om-broccoli
halsorevolutionen
rss-spraket
bildningspodden
hacka-livet
rss-experimentet
medicinvetarna
rss-lara-fran-larda-en-fackbok-och-en-forfattare